Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Anderson

Sports Medicine San Diego, CA Doctor of Osteopathy

NPI 1437172533 CMS profile 155169

1945 Garnet Ave, San Diego, CA 92109

Open in the dashboard

General payments

$1,655

79 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kenneth Anderson of San Diego, CA is reported in the CMS Open Payments database as having received $1,655 across 79 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $224 7
2024 General $235 10
2023 General $188 9
2022 General $261 14
2021 General $380 19
2020 General $289 15
2019 General $79 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Anderson
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Kenneth Anderson were reported at $224. Among 1,257 Sports Medicine profiles paid that year, the median was $114 and the middle half received between $39 and $293.

Show as a table
Year Kenneth Anderson Sports Medicine median Middle half National median
2019 $79 $119 $35–$362 $163
2020 $289 $77 $24–$275 $114
2021 $380 $104 $28–$340 $132
2022 $261 $94 $31–$272 $149
2023 $188 $91 $34–$271 $160
2024 $235 $126 $38–$294 $164
2025 $224 $114 $39–$293 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $414 21 payments
  2. Pfizer Inc. $172 10 payments
  3. GlaxoSmithKline, LLC. $167 8 payments
  4. Boston Scientific Corporation $104 2 payments
  5. Allergan Inc. $98 5 payments
  6. Genentech USA, Inc. $80 4 payments
  7. Eisai Inc. $74 4 payments
  8. Hologic, LLC $66 3 payments
  9. Gilead Sciences, Inc. $59 3 payments
  10. AstraZeneca Pharmaceuticals LP $54 3 payments
  11. Other $367 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,639 78 payments
  2. Education $16 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY Neuroscience $337 17 payments
  2. TRELEGY ELLIPTA $167 8 payments
  3. WaveWriter Alpha Prime 16 $104 2 payments
  4. QULIPTA $90 4 payments
  5. Dayvigo $74 4 payments
  6. Xofluza $68 3 payments
  7. Aptima $66 3 payments
  8. UBRELVY Neuroscience $59 3 payments
  9. VRAYLAR $58 3 payments
  10. NURTEC ODT $52 3 payments
  11. Other $760 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 77 drugs

Part D claims

2,381

Median for Family Practice: 1,826

Drug cost

$47,346

Median for Family Practice: $120,094

Branded share of claims

15.2%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 21 $18,996
Testosterone Generic 15 $2,234
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 86 $1,691
Atorvastatin Calcium Generic 155 $1,223
Ezetimibe Generic 19 $997
Rosuvastatin Calcium Generic 62 $965
Celecoxib Generic 21 $946
Lisinopril Generic 95 $884
Ventolin Hfa Albuterol Sulfate Brand 15 $838
Butalbital-Acetaminophen-Caffe Butalb/Acetaminophen/Caffeine Brand 18 $760

The 10 drugs with the highest cost, of 77 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$120,923

Of which drugs: $1,569

Medicare patients

422

Average age 75

Services billed

3,111

230 women, 192 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 54%
Arthritis 47%
Ischemic heart disease 23%
Atrial fibrillation 16%
Depression 15%
Osteoporosis 15%
Cancer 13%
Diabetes 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 27 522 $358
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 52 62 $323

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $56
$56 — —
PAXLOVID
  • PFIZER INC. $22
$22 — —
UBRELVY
  • AbbVie, Inc. $14
$14 — —
QULIPTA
  • AbbVie, Inc. $14
$14 — —
NURTEC ODT
  • PFIZER INC. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

79 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record